Image source: Getty Images.
Exelixis (NASDAQ: EXEL) is scheduled to release earnings after the closing bell on Wednesday, when investors will get a first look at how quickly sales of its kidney cancer drug Cabometyx can blast off.
Image source: Getty Images.
Exelixis (NASDAQ: EXEL) is scheduled to release earnings after the closing bell on Wednesday, when investors will get a first look at how quickly sales of its kidney cancer drug Cabometyx can blast off.